SCHEMBL22718097

SCHEMBL22718097

COc1ccc(CN(C)S(=O)(=O)c2ccc(Nc3ccc(C(C)(C)C)cn3)c(-c3cn(C)cn3)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 1/20 0.42
▸ YAP1 P46937 1/20 0.42
▸ ACLY P53396 1/20 0.37
▸ PTGER2 P43116 2/20 0.37
▸ MAPK8 P45983 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CCR9 P51686 2/20 0.35
▸ KAT8 Q9H7Z6 2/20 0.35
▸ NR1I2 O75469 1/20 0.34
▸ TTK P33981 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ CCR6 P51684 1/20 0.33
▸ BMP1 P13497 1/20 0.33
▸ ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438933 1.00 TEAD1 (0.42) TEAD1YAP1ACLYPTGER2MAPK8
SCHEMBL29438934 1.00 TEAD1 (0.42) TEAD1YAP1ACLYPTGER2MAPK8
SCHEMBL29438915 0.93 TEAD1 (0.49) TEAD1YAP1MAPK8MAPK10MEN1
SCHEMBL22718251 0.93 TEAD1 (0.49) TEAD1YAP1MAPK8MAPK10MEN1
SCHEMBL29438917 0.93 TEAD1 (0.49) TEAD1YAP1MAPK8MAPK10MEN1
SCHEMBL24496182 0.90 TEAD1 (0.39) TEAD1YAP1ACLYMAPK8MAPK10
SCHEMBL29648333 0.90 TEAD1 (0.39) TEAD1YAP1ACLYMAPK8MAPK10
SCHEMBL22718047 0.89 TEAD1 (0.42) TEAD1YAP1ACLYMAPK8MAPK10
SCHEMBL29438890 0.89 TEAD1 (0.42) TEAD1YAP1ACLYMAPK8MAPK10
SCHEMBL24495997 0.89 TSHR (0.38) TEAD1YAP1ACLYMAPK8MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885ACLY 875/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885ACLY 875/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885ACLY 875/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885ACLY 875/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 TEAD1 7/4885YAP1 13/4885ACLY 3978/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885ACLY 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback